Fate Therapeutics, Inc Q4 Loss Misses Estimates

Fate Therapeutics, Inc (FATE) reported Loss for fourth quarter that missed the Street estimates.

The company's earnings came in at -$52.15 million, or -$0.44 per share. This compares with -$44.12 million, or -$0.45 per share, last year.

Analysts on average had expected the company to earn -$0.42 per share. Analysts' estimates typically exclude special items.

The company's revenue for the period rose 10.7% to $1.86 million from $1.68 million last year.

Fate Therapeutics, Inc earnings at a glance (GAAP) :

-Earnings: -$52.15 Mln. vs. -$44.12 Mln. last year.
-EPS: -$0.44 vs. -$0.45 last year.
-Revenue: $1.86 Mln vs. $1.68 Mln last year.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com